A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors

NCT07682870 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Solid Tumor

Interventions

DRUG: Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection

Sponsor

Virogin Biotech Ltd.